Altimmune, Inc. (NASDAQ:ALT) Receives $20.20 Average PT from Analysts

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has received an average recommendation of "Buy" from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.20.

A number of research firms have recently commented on ALT. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, April 3rd. William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th.

Insider Buying and Selling at Altimmune

In related news, CFO Gregory L. Weaver purchased 10,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.10% of the company's stock.

Institutional Trading of Altimmune

A number of hedge funds have recently made changes to their positions in ALT. Ameriprise Financial Inc. boosted its position in shares of Altimmune by 35.6% in the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares in the last quarter. RFG Advisory LLC bought a new stake in shares of Altimmune in the 1st quarter worth approximately $1,622,000. Nuveen LLC bought a new stake in shares of Altimmune in the 1st quarter worth approximately $1,304,000. Invesco Ltd. boosted its position in shares of Altimmune by 679.2% in the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company's stock worth $1,781,000 after purchasing an additional 215,375 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Altimmune by 139.8% in the 4th quarter. Millennium Management LLC now owns 345,637 shares of the company's stock worth $2,492,000 after purchasing an additional 201,484 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Trading Down 0.0%

ALT stock traded down $0.00 during trading on Monday, reaching $5.78. 596,737 shares of the stock were exchanged, compared to its average volume of 2,833,277. The firm has a market cap of $444.99 million, a P/E ratio of -3.75 and a beta of 1.13. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16. The firm's 50 day moving average is $5.10 and its 200 day moving average is $6.58.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.